✦ LIBER ✦

Everolimus in relapsed Hodgkin's lymphoma: Something exciting or a case of caveat mTOR?

✍ Scribed by Simon Rule

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 77 KB
Volume: 85
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.21704

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase II trial of the oral mTOR inhibi

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

✍ Patrick B. Johnston; David J. Inwards; Joseph P. Colgan; Betsy R. Laplant; Brian 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 217 KB

A multicenter phase II study of darinapa

A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma

✍ Peter J. Hosein; Michael D. Craig; Martin S. Tallman; Ralph V. Boccia; Brian L. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 850 KB

ABVD: doxorubicin,

Cladribine in the treatment of advanced

Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma

✍ Anil Tulpule; Gary Schiller; Laura A. Harvey-Buchanan; Myung Lee; Byron M. Espin 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 2 views

## BACKGROUND. Cladribine (2-chlorodeoxyadenosine) is a purine nucleoside analog with cytotoxic activity against both resting and proliferating cells. Clinical studies with cladribine have reported antitumor activity against various hematologic malignancies.